Novo Nordisk A/S $NVO Position Decreased by Zevin Asset Management LLC

Zevin Asset Management LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 45.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,017 shares of the company’s stock after selling 34,723 shares during the quarter. Zevin Asset Management LLC’s holdings in Novo Nordisk A/S were worth $2,276,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Lockheed Martin Investment Management Co. increased its stake in Novo Nordisk A/S by 179.4% in the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after purchasing an additional 27,900 shares in the last quarter. Martin Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 53.8% in the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after acquiring an additional 41,129 shares in the last quarter. Markel Group Inc. raised its holdings in shares of Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after acquiring an additional 110,061 shares during the period. Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $1,294,000. Finally, WCM Investment Management LLC boosted its stake in Novo Nordisk A/S by 3.7% in the 3rd quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company’s stock worth $151,636,000 after purchasing an additional 97,477 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $47.43 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $211.77 billion, a PE ratio of 13.67 and a beta of 0.67. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The company has a 50 day moving average price of $53.77 and a two-hundred day moving average price of $53.30.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Analysts Set New Price Targets

NVO has been the topic of several recent analyst reports. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. Morgan Stanley restated an “underweight” rating and set a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Finally, Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.